Professional Documents
Culture Documents
PREMEDICATION
*If acute cholinergic syndrome appears atropine sulphate 250micrograms should be
administered by subcutaneous injection unless clinically contraindicated.
The manufacturer recommends the use of prophylactic atropine sulphate with subsequent
doses of irinotecan.
DOSE FORM
Capecitabine available as 500mg and 150mg tablets.
APPROVED INDICATIONS
Treatment of Advanced Colorectal Cancer, in patients who would otherwise be considered
for Irinotecan-MdG (FOLFIRI).
ELIGIABILITY CRITERIA
Colorectal cancer patients with adequate renal function.
EXCLUSION CRITERIA
Patients with baseline renal function less than 30 ml/min.
Patients incapable of managing oral chemotherapy themselves or with the assistance
of a carer
Patients with swallowing difficulties
REVIEW BY CLINICIAN
To be reviewed by either a Nurse, Pharmacist or Clinician before every cycle.
ADMINISTRATION NOTES
Irinotecan must only be given in units where clear arrangements are made to manage
possible toxicity related out of hour's admissions. Patients must be made aware of the
risk of delayed diarrhoea occurring 24 hours after the administration of Irinotecan and
at any time before the next cycle. This means supplying information sheets to the
patient and if appropriate to their GP.
Early onset diarrhoea (within the first 24 hours). Can be a result of acute cholinergic
syndrome and may occur in 9% of patients. Symptoms are short lasting and respond
within minutes to administration of atropine (0.25-1mg subcutaneously)
Delayed diarrhoea must be treated immediately with high dose Loperamide (4mg after
first loose stool and 2mgs every 2 hours, to a maximum of 16 (2mg) tablets in 24 hours.
Hospitalise if condition not resolved in 48 hours.
Capecitabine should start on the evening of day 1 and continue until the morning
of day 15.
Capecitabine should be omitted if Grade II toxicity occurs. It can recommence (see
Dose Reductions) if toxicity resolves, however the treatment should still stop on day 15.
(i.e. Doses are omitted not delayed).
Note: Grade II Toxicity includes: Diarrhoea defined as an increase of 4-6 stools per day
or nocturnal stools.
TOXICITIES
Acute cholinergic syndrome (defined as early diarrhoea and various other symptoms
such as sweating, abdominal cramping, lacrimation, myosis and salivation)
Diarrhoea –risk of severe delayed diarrhoea – can be life threatening
Nausea and Vomiting
Stomatitis
Palmar/Plantar Erythrodysesthesia (PPE) - Can be severe, patients must be
forewarned
Pyrexia, fatigue, asthenia, anorexia
Myelosuppression
Hyperbilirubinemia
Cardiotoxicity - Occasionally patients may experience coronary artery spasm. Stop
Treatment with fluoropyrimidine therapy if this occurs.
Non-haematological toxicity:
Diarrhoea
Grade 1 (watery stool 2-3 times/day) Loperamide 4mg then 2mg QDS PRN.
Grade 2 (watery stool 4-6 times/day) Delay treatment until recovered and give full
dose
Grade 3/4 (watery stool >7 times/day) Delay until recovered and resume treatment
at 25% reduced dose of oxaliplatin and
irinotecan
Once the capecitabine dose has been reduced, it should not be increased at a later time.
Omitted doses are not replaced or restored, instead the patient should resume the
planned treatment cycle.
Hepatic impairment
Administration of capecitabine should be interrupted if treatment-related elevations in
bilirubin of > 3.0 x ULN or treatment-related elevations in hepatic aminotransferases (ALT,
AST) of > 2.5 x ULN occur. Treatment with capecitabine monotherapy may be resumed
when bilirubin decreases to ≤ 3.0 x ULN or hepatic aminotransferases decrease to ≤ 2.5 x
ULN.
Renal function
GFR Capecitabine Oxaliplatin
30-50 ml/min 25% dose reduction No action
< 30 ml/min Contact prescriber Contact prescriber
REFERENCES:
1. Reinacher-Schick AC et al. Activity of the combination of bevacizumab (Bev) with
capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in
advanced colorectal cancer (ACRC): a randomized phase II study of the AIO Colorecal
Study Group (AIO trial 0604). Am Soc Clin Oncol 2008; Abstract 4030
2. Koopman M et al. Sequential versus combination chemotherapy with capecitabine,
irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III
randomised controlled trial. Lancet 2007; 370: 135-42
3. Ducreux M et al. Efficacy and safety of bevacizumab (BEV)-based combination
regimens in patients with metastatic colorectal cancer (mCRC): Randomised phase II
study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD13/0503 study). Am
Soc Clin Oncol, Annual Meeting 2009; Abstract 4086 and associated oral presentation
1.4 Protocol reviewed, parameters updated from Chemocare. DPD toxicity advice added